CP
The startup develops hypoxia-activated prodrugs (HAPs) that enhance the efficacy of conventional anti-cancer treatments by targeting the tumor microenvironment. This approach enables physicians to provide more effective and well-tolerated therapies for cancer patients, improving treatment outcomes and patient quality of life.
Updated 18 months ago
Funding
$17.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops hypoxia-activated prodrugs (HAPs) that enhance the efficacy of conventional anti-cancer treatments by targeting the tumor microenvironment. This approach enables physicians to provide more effective and well-tolerated therapies for cancer patients, improving treatment outcomes and patient quality of life.